Kurtais 2008.

Methods	Parallel group design. Method of randomisation not stated. Method of analysis not described. Treated as outpatients 3 times a week for 6 weeks for a total period of 12 hours (40‐minute sessions). Assessed at baseline and 7 weeks after baseline assessments. Assessors were blinded.
Participants	13 participants in the treadmill group and 14 in the control group. 1 dropout in the treadmill group and 2 in the control group. No baseline characteristics given for dropouts. Participants' mean age 63.8 years (treadmill), 65.7 years (control); male/female 5/7 (treadmill), 7/5 (control); Hoehn and Yahr 2.5 (treadmill), 2.2 (placebo). Duration of PD 5.3 years (treadmill), 5.4 years (control). Inclusion criteria: stable antiparkinsonian medication, ability to walk independently, not participated in a rehabilitation program in the previous 3 months. Exclusion criteria: severe cognitive impairments or severe musculoskeletal, cardiopulmonary, neurological, or other system disorders.
Interventions	Treadmill: gait training on a treadmill 3 times a week, attaining 70% to 80% of maximal heart rate. Either speed or incline was gradually increased over time. Control: untreated. Drug therapy was stable during the trial.
Outcomes	20‐m walking time. Timed U‐turn task. Turning around a chair. Climbing up and down a flight of stairs at participants' preferred speed. Standing on one foot. Standing up from an armless chair. Rate global physical status. Cardiopulmonary fitness levels. Examinations were done during the participants 'on' phase.
Notes	Both groups were taught exercises to maintain flexibility and range of motion. One patient from the treadmill group was excluded as the result of noncompliance.
Risk of bias
Bias	Authors' judgement	Support for judgement
Eligibility Criteria	Low risk
Randomisation Method	Unclear risk	Randomisation method was not stated.
Concealment of Allocation	Unclear risk	Randomisation method was not stated.
Similarity at Baseline	Low risk
Withdrawals Described	High risk	11% withdrawals.
Intention To Treat Analysis	Unclear risk	Method of analysis not described.
Cointerventions Constant	Low risk	Drug therapy was stable during the trial.
Blinded Assessors	Low risk	Assessors were blinded to group allocation.